Abraxis: Studies confirm activity of Abraxane to treat lung cancer

By Elaine Rigoli

Tampa, Fla., June 6 - Abraxis BioScience, Inc. said data from multiple phase 2 studies with Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) as first-line treatment for late-stage non-small cell lung cancer showed improved antitumor benefits over the solvent-based taxane treatment.

These data form the basis for the phase 3 registration trial, according to a news release.

These early studies show efficacy results that seem to be better than typically seen with solvent-based taxane therapy in advanced lung cancer treatment, officials said.

The protocol for this trial is being discussed with the Food and Drug Administration and the registrational phase 3 trial is expected to begin in the second half of 2006.

Abraxis is a global biopharmaceutical company based in Los Angeles.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.